Exenatide

Exenatide has been studied in 237 papers since 2005: 14 trials and 47 observational studies in people, 40 in animals, 17 in cells, 114 reviews; 129 in the past year. It is an approved medicine. The newest story, Nov 9, 2026: “Exenatide lowered protein-based age scores in people”.

InterventionGLP-1 receptor agonistsApproved 2005

237 papers study it16 more mention it158 findingsUpdated

PubChemChEBIMeSH

More peptides

34 new papers in 30 daysSee all 246 papers on exenatide

At a glance

Exenatide extends lifespan in a study of Huntington’s disease mice and improves memory in a study modeling midlife brain aging in mice. Independent labs reproduce HbA1c and weight reductions in humans; a trial reports increased hypoglycemia in people with type 2 diabetes taking metformin and a sulfonylurea. Some papers declare developer ties, and AstraZeneca and Peptron sponsor trials.

158 findings in 76 papers from 2005 to 2026, 16 of them since April 2026

Independent labs found the same change in cells, mice and people. 58 independent labs in 20 countries; 175 trials, 46 about aging, 55 with no results posted.

“Exenatide, cagrilinitide, orforglipron were not associated with diarrhea risk.”
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysisInternational journal of obesity (2005)2025doi:10.1038/s41366-025-01859-6

None of its findings points the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
  • 58 independent labs in 20 countries
  • 175 trials, 46 about aging, 55 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 15 of 145 findings with company ties
  • 75 of 175 trials sponsored by its developers
  • Human trial14
  • Humans45
  • Animals38
  • Model organisms1
  • Cells17
  • In silico3

14 studies gave exenatide to people and measured what changed.

What changedDesignPeopleSource

down: Decreases organ-enriched proteomic age gaps6 organ clocks decreased; interaction p<0.05

Randomized trial12 months3,973 peopleType 2 diabetesAHA Scientific Sessions 2026 abstract, Nov 2, 2026

up: Increases pancreatic digestive enzymes

down: Decreases NT-proBNP

Randomized trial12 months3,973 peopleType 2 diabetesAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Decreases hepatic insulin resistance

Treated cohortIn vitro and in vivoInternational immunopharmacology, Feb 21, 2026

up: Increases GLP-1

no change: Has no effect on glucagon

no change: Has no effect on GIP

Randomized trial8 weeksPatient cohortsThe Journal of clinical endocrinology and metabolism, Jan 28, 2026

up: Improves menstrual regularityp<0.001

Review of trials730 people pooledIn PCOS patients, two studiesENDO 2025 abstract, Oct 22, 2025

What did studies of exenatide find?

122

Studies of exenatide measured 122 outcomes; the most studied are inflammation (5 studies), body weight (4) and apoptosis (4).

Inflammation

downin mice2downin cells1downin humans1downin rats1

5 studies
  1. Exenatide decreases inflammation in mice (sepsis-induced depression).

    “Exenatide downregulated tumor necrosis factor-α, interleukin-6, and adrenocorticotropic hormone levels”

    Animalssepsis-induced depressionintraperitoneal1 mg/kg/day14 days

    Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model

    Neuroscience

  2. Exenatide inhibits inflammation in doxorubicin-treated rats.

    “Exenatide co-treatment significantly attenuated all DOX-induced changes.”

    Animalsin doxorubicin-treated ratsmales

    GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study

    Medicina (Kaunas, Lithuania)

  3. Exenatide inhibits inflammation in humans.

    “Additionally, Ex-4 plays an important role in anti-inflammatory actions which are necessary both in the case of asthma and Parkinson's disease.”

    Review

    Beneficial Influence of Exendin-4 on Specific Organs and Mechanisms Favourable for the Elderly with Concomitant Obstructive Lung Diseases

    Brain sciences

  4. Exenatide decreases inflammation in hyperglycemia-exposed cardiomyocyte models.

    “Exenatide treatment inhibited inflammation, improved cardiomyocyte contractile function, and rescued cardiomyocyte viability.”

    Cellsin hyperglycemia-exposed cardiomyocyte models

    Exenatide inhibits NF-κB and attenuates ER stress in diabetic cardiomyocyte models

    Aging

  5. Exenatide decreases inflammation in ApoE-/- mice under chronic immobilization stress.

    “lowered levels of peroxisome proliferator-activated receptor-α, gp91phox osteopontin, C-X-C chemokine receptor-4, toll-like receptor-2 (TLR2), TLR4, and cathepsins K, L, and S mRNAs and/or proteins”

    Animalsin ApoE-/- mice under chronic immobilization stressaortic plaque12 weeks

    Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress

    Atherosclerosis

More on Inflammation

Body weight

downin humans3downin mice1

4 studies
  1. Exenatide decreases body weight in humans (type 2 diabetes treated with metformin and a sulfonylurea) (-1.6 +/- 0.2 kg vs -0.9 +/- 0.2 kg placebo).

    “Both exenatide arms demonstrated significant weight loss (-1.6 +/- 0.2 kg from baseline each exenatide arm, -0.9 +/- 0.2 kg placebo; P < or = 0.01 vs. placebo).”

    Human trialtype 2 diabetes treated with metformin and a sulfonylurea30 weeks

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

    Diabetes care

  2. Exenatide is linked with lower body weight in humans (patients aged ≥65 years) (-1.6 kg vs 0.2 kg (EQW vs BI)).

    “Weight changed by -1.6 kg among EQW initiators compared with 0.2 kg among BI initiators.”

    Humanspatients aged ≥65 yearsonce weekly1 year

    Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States

    Diabetes, obesity & metabolism

  3. Exenatide decreases body weight in mice (diet-induced obesity; relative to vehicle) (Up to 22.6% of starting body weight reported across Ex4 and Ex4-Fc).

    “Ex4 and Ex4-Fc vectors, but not GLP-1 or Gly8 vectors, produced significant reductions in body weight”

    Animalsdiet-induced obesity; relative to vehiclePHP.eB scAAV5x1012 vg/kg21 days

    Peptide Sequence Determines the Efficacy of Single-Dose AAV-Vectorized GLP-1R Agonists in Diet-Induced Obese Mice

    bioRxivPreprint

  4. Exenatide decreases body weight in humans (mild weight loss, less than 3.2% of initial weight).

    “Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.”

    Review

    Anti-diabetic drugs and weight loss in patients with type 2 diabetes

    Pharmacological research

Apoptosis

downin mice2downin mouse cells1downin rats1

4 studies
  1. Exenatide decreases apoptosis in mouse cells (Aβ1-40 exposure; pretreatment).

    “pretreatment with EX-4 alleviated apoptosis and restored calcium homeostasis both in vivo and in vitro.”

    CellsAβ1-40 exposure; pretreatmentretinal pigment epithelial cell

    Exendin-4 alleviates Aβ1-40-induced apoptosis and calcium dysregulation in RPE cells through the CHP1/NHE1 complex

    Biochemical pharmacology

  2. Exenatide decreases apoptosis in D-galactose-induced hyposalivation.

    “TUNEL analysis revealed a decrease in apoptotic cells in the salivary gland”

    Animalsin D-galactose-induced hyposalivationsalivary gland2 weeks

    Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4

    European journal of pharmacology

  3. Exenatide decreases apoptosis in mice (high-fat diet-induced obesity).

    “Here, we show that exenatide treatment reversed HFD induced TECs injuries, including TECs apoptosis and SIRT1 downregulation.”

    Animalshigh-fat diet-induced obesitytubular epithelial cells

    Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells

    Frontiers in endocrinology

  4. Exenatide inhibits apoptosis in mice (wild-type mice employed as a model of mid-life brain aging).

    “the drug promotes the activation of the BDNF-TrkB neurotrophic axis and inhibits apoptosis by decreasing p75NTR-mediated signaling.”

    Animalswild-type mice employed as a model of mid-life brain agingbrain2 months

    Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice

    Neurobiology of aging

More on Apoptosis

Motor function

upin humans3

3 studies
  1. Exenatide improves motor function in humans (MD = −2.93 on the MDS-UPDRS Part III).

    “only short-acting formulations (such as exenatide) show statistically significant motor improvements in trials (MD = −2.93 on the MDS-UPDRS Part III)”

    Reviewshort-acting formulation

    Neuroprotective Potential of GLP-1 Receptor Agonists in Neurodegenerative Diseases: Narrative Review

    Biuletyn Głównej Biblioteki Lekarskiej

  2. Exenatide improves motor function in humans (Parkinson's disease; early-phase trials) (Sustained up to twelve months after treatment cessation).

    “Early-phase exenatide trials reported sustained motor improvements lasting up to twelve months after treatment cessation”

    ReviewParkinson's disease; early-phase trials

    Neuroprotective and Disease-Modifying Potential of GLP-1 Receptor Agonists in Parkinson’s Disease: A systematic Review of randomized Controlled Trials and Cohort Study

    International Journal of Health Engineering and Technology

  3. Exenatide improves motor function in humans (Parkinson's disease).

    “Whilst in PD, the GLP-1 receptor agonist exenatide is effective in restoring motor function and cognition.”

    ReviewParkinson's disease

    Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease

    Ageing research reviews

SIRT1

upin human cells1upin mice1upin mouse cells1

3 studies
  1. Exenatide increases SIRT1 in high-fat diet-treated mice.

    “upregulated SIRT1 expression, and downregulated Txnip expression in kidneys of high-fat diet-treated C57BL/6J mice”

    Animalsin high-fat diet-treated micekidney

    SIRT1-dependent deacetylation of Txnip H3K9ac is critical for exenatide-improved diabetic kidney disease

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  2. Exenatide activates SIRT1 in human cells (palmitate-stimulated HK2 cells).

    “exenatide treatment reversed the downregulation of SIRT1”

    Cellspalmitate-stimulated HK2 cellsrenal tubular cells

    Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells

    Frontiers in endocrinology

  3. Exenatide increases SIRT1 in differentiated 3T3-L1 adipocytes.

    “exendin-4 increased lipolysis and fatty acid oxidation by upregulating SIRT1 expression and activity in differentiated 3T3-L1 adipocytes”

    Cellsin differentiated 3T3-L1 adipocytes

    GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1

    Diabetologia

More on SIRT1

HbA1c

downin humans3−1% placebo-adjusted

3 studies
  1. Exenatide decreases HbA1c in humans (combined with metformin; similar reduction to acarbose) (9.72±1.38 to 7.09±0.60%).

    “Glucose control, measured by HbA1c (GLP-1: 9.72±1.38; 7.09±0.60%, P<0.001, 9.46±1.25; 7.42±0.84%, P<0.001, respectively)”

    Human trialcombined with metformin; similar reduction to acarbose3 months

    Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial

    Obesity research & clinical practice

  2. Exenatide decreases HbA1c in humans (type 2 diabetes treated with metformin and a sulfonylurea) (-1.0% placebo-adjusted).

    “yielding placebo-adjusted reductions of -1.0% (10 microg) and -0.8% (5 microg)”

    Human trialtype 2 diabetes treated with metformin and a sulfonylurea10 microg b.i.d.30 weeks

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

    Diabetes care

  3. Exenatide is linked with lower HbA1c in humans (patients aged ≥65 years) (-0.50 vs -0.31 percentage points from baseline to Q4 (EQW vs BI)).

    “HbA1c changed by -0.50 and -0.31 percentage points from baseline to Q4 for EQW and BI initiators, respectively”

    Humanspatients aged ≥65 yearsonce weeklybaseline to Q4

    Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States

    Diabetes, obesity & metabolism

More on HbA1c

Adiponectin

upin mouse cells2upin humans1

3 studies
  1. Exenatide increases adiponectin in humans (compared with acarbose at 3 months) (P=0.025 versus control group).

    “Adiponectin level was higher in the GLP-1 group than the control group at 3 months (P=0.025).”

    Human trialcompared with acarbose at 3 months3 months

    Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial

    Obesity research & clinical practice

  2. Exenatide increases adiponectin in stressed mice.

    “Exenatide also stimulated APN expression of preadipocytes”

    Cellsin stressed micepreadipocytes

    Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress

    Atherosclerosis

  3. Exenatide increases adiponectin in 3T3-L1 cells.

    “the GLP-1 receptor agonist exenatide stimulated APN expression in 3T3-L1 cells.”

    Cellsin 3T3-L1 cells

    Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress

    International journal of cardiology

More on Adiponectin

Intracranial pressure

downin humans2

2 studies
  1. Exenatide decreases intracranial pressure in humans (idiopathic intracranial hypertension).

    “exenatide lowers intracranial pressure in idiopathic intracranial hypertension because the choroid plexus lies outside the blood-brain barrier”

    Reviewidiopathic intracranial hypertension

    Reversibility and Access: A Two-Axis Framework for Glucagon-Like Peptide-1 Receptor Agonists Across the Neurological Spectrum, and a Falsifiable Analgesic Hypothesis for Chronic Migraine

    Preprints.orgPreprint

  2. Exenatide decreases intracranial pressure in humans (small randomized controlled trial).

    “In a small RCT, exenatide significantly lowered ICP within hours of administration.”

    Reviewsmall randomized controlled trialwithin hours of administration

    Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review

    The journal of headache and pain

More on Intracranial pressure

Oxidative stress and ROS signaling

downin rats2

2 studies
  1. Exenatide inhibits oxidative stress and ROS signaling in doxorubicin-treated rats.

    “Exenatide co-treatment significantly attenuated all DOX-induced changes.”

    Animalsin doxorubicin-treated ratsmales

    GLP-1 Receptor Agonist Exenatide Protects Against Doxorubicin-Induced Cardiotoxicity Through the SIRT1 Pathway: An Electrocardiographic, 99mTc-PYP Scintigraphic, and Biochemical Study

    Medicina (Kaunas, Lithuania)

  2. Exenatide decreases oxidative stress and ROS signaling in early-stage streptozotocin-diabetic rats.

    “Four days after intravitreal EX4 treatment, retinal cell death and ROS level in retinas reduced significantly”

    Animalsin early-stage streptozotocin-diabetic ratsintravitreal injectionretina4 days

    The glucagon like peptide 1 analogue, exendin-4, attenuates oxidative stress-induced retinal cell death in early diabetic rats through promoting Sirt1 and Sirt3 expression

    Experimental eye research

More on Oxidative stress and ROS signaling

Lifespan

upin mice1upin worms1+34%

2 studies
  1. Exenatide extends lifespan in worms (CL4176 worms expressing Aβ1-42) (+34.39%).

    “Exendin-4 at 0.5 mg/ml had been shown to extend life by 34.39% in CL4176”

    Model organismsCL4176 worms expressing Aβ1-420.5 mg/ml

    Exendin-4 alleviates β-Amyloid peptide toxicity via DAF-16 in a Caenorhabditis elegans model of Alzheimer's disease

    Frontiers in aging neuroscience

  2. Exenatide extends lifespan in N171-82Q HD mice.

    “Exendin-4 or GLP-1-Tf (but not insulin) treatment also improved pancreatic morphology, motor coordination, and increased life span.”

    Animalsin N171-82Q HD mice

    Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy

    The Journal of biological chemistry

Organ-enriched proteomic age gaps

downin humans1

1 study
  1. Exenatide decreases organ-enriched proteomic age gaps in humans (type 2 diabetes; compared with placebo) (6 organ clocks decreased; interaction p<0.05).

    “6 decreased with 12 months of therapy, including heart, pancreas, brain, artery, adipose and muscle”

    Human trialtype 2 diabetes; compared with placeboheart, pancreas, brain, artery, adipose tissue, and muscleonce-weekly12 monthsn = 3,973

    Exenatide lowered protein-based age scores in people

    AHA Scientific Sessions 2026 abstract

More on Organ-enriched proteomic age gaps

NT-proBNP

downin humans1

1 study
  1. Exenatide decreases NT-proBNP in humans (type 2 diabetes; compared with placebo).

    “Proteins that decreased more with EQW vs. placebo (n=320) included tenascin, NT-proBNP”

    Human trialtype 2 diabetes; compared with placeboonce-weekly12 monthsn = 3,973

    Diabetes drug altered proteins linked to heart risk

    AHA Scientific Sessions 2026 abstract

More on NT-proBNP

Pancreatic digestive enzymes

upin humans1

1 study
  1. Exenatide increases pancreatic digestive enzymes in humans (type 2 diabetes; compared with placebo).

    “Proteins that increased more with EQW vs. placebo (n=207) were predominated by pancreatic digestive enzymes”

    Human trialtype 2 diabetes; compared with placeboonce-weekly12 monthsn = 3,973

    Diabetes drug altered proteins linked to heart risk

    AHA Scientific Sessions 2026 abstract

More on Pancreatic digestive enzymes

GDF-15

upin humans1

1 study
  1. Exenatide increases GDF-15 in humans (16 weeks of add-on treatment) (721.9 (513.6, 997.8) to 741.4 (510.0, 1203.4) pg/mL, p = 0.031).

    “GDF15 levels were significantly increased from baseline following 16 weeks of exenatide treatment”

    Human trial16 weeks of add-on treatment16 weeksn = 166

    Circulating GDF15 and HbA1c Response to Add-On Exenatide Therapy in Type 2 Diabetes: A Post Hoc Analysis from a Multicenter Trial

    Biomedicines

More on GDF-15

GIP

no changein humans1

1 study
  1. Exenatide showed no clear effect on GIP in humans (combined with basal insulin therapy, following cessation).

    “between-group comparisons of baseline-adjusted area-under-the-curve (AUC) for glucagon and GIP (both P = NS)”

    Human trialcombined with basal insulin therapy, following cessation8 weeks

    Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin

    The Journal of clinical endocrinology and metabolism

More on GIP

All 122

What is exenatide linked with?

13

Studies link exenatide with 13 measures, among them inflammatory and Alzheimer’s-related biomarkers, gastroesophageal reflux disease and nervousness.

Inflammatory and Alzheimer’s-related biomarkers

mixedin humans1

1 study
  1. Exenatide is associated with inflammatory and Alzheimer’s-related biomarkers in humans.

    “Exenatide showed exploratory modulation of inflammatory and Alzheimer’s-related biomarkers.”

    Review

    Systematic review of the neuroprotective potential of GLP1 receptor agonists and SGLT2 inhibitors in Alzheimer’s disease and cognitive impairment

    Discover Neuroscience

More on Inflammatory and Alzheimer’s-related biomarkers

Gastroesophageal reflux disease

downin humans1

1 study
  1. Exenatide is associated with gastroesophageal reflux disease in humans (FAERS) (ROR 0.60 (95% CI 0.46 to 0.77)).

    “Exenatide showed an inverse association in FAERS (ROR, 0.60; 95% CI, 0.46 to 0.77).”

    HumansFAERS

    Multi-Database Pharmacovigilance Analysis of Gastroesophageal Reflux Disease Associated with GLP-1 Receptor Agonists: A Cross-National Signal Validation Study

    Gut and liver

More on Gastroesophageal reflux disease

Nervousness

upin humans1

1 study
  1. Exenatide is linked with a higher risk of nervousness in humans (disproportionality analysis of FAERS reports) (ROR 4.03; 95% CI 3.70-4.40).

    “Exenatide generated the highest psychiatric signal: nervousness (ROR 4.03; 95%CI 3.70-4.40)”

    Humansdisproportionality analysis of FAERS reports

    Neuro-Adverse Events Associated with GLP-1 Receptor Agonists: A Study Based on the FAERS Database and External Validation Using NHANES Database

    medRxivPreprint

More on Nervousness

Cognitive function

mixedin humans1

1 study
  1. Exenatide is associated with cognitive function in humans (moderate cognitive impairment and early Alzheimer's disease).

    “human clinical trials have so far shown conflicting findings about the cognitive and clinical effects of Ex-4 in moderate cognitive impairment (MCI) and early AD.”

    Reviewmoderate cognitive impairment and early Alzheimer's disease

    Beyond Glycemic Control: Exploring the Prospective of Exendin-4 Clinical Utility as a Disease-Modifying Agent in Alzheimer's Disease; Preclinical and Clinical Evidence

    Journal of Pioneering Medical Science

Muscle atrophy

downin humans1

1 study
  1. Exenatide is associated with muscle atrophy in humans (disproportionality versus all other FAERS drugs) (ROR 0.26 (95% CI 0.12-0.55)).

    “exenatide (ROR = 0.26, 95 % CI = 0.12-0.55) and liraglutide (ROR = 0.27, 95 % CI = 0.09-0.83) were associated with significantly lower reporting odds”

    Humansdisproportionality versus all other FAERS drugs

    Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study

    Clinical nutrition (Edinburgh, Scotland)

More on Muscle atrophy

Acute kidney injury

upin humans1

1 study
  1. Exenatide is associated with acute kidney injury in humans (FAERS reports, disproportionality analysis) (ROR 1.14 (1.05-1.23)).

    “semaglutide [ROR 1.65 (1.50-1.81)] and exenatide [ROR 1.14 (1.05-1.23)] showed also significant associations with the development of AKI”

    HumansFAERS reports, disproportionality analysis

    MON-527 Association of Acute kidney injury with commonly prescribed glucagon-like peptide 1 receptor Agonists: A Pharmacovigilance Analysis

    ENDO 2025 abstract

More on Acute kidney injury

Vomiting

upin humans1

1 study
  1. Exenatide raises the risk of vomiting in humans (network comparison with other GLP-1 receptor agonists).

    “Exenatide exhibited the highest incidence of vomiting”

    Human trialnetwork comparison with other GLP-1 receptor agonists

    Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis

    Frontiers in pharmacology

More on Vomiting

Mortality

downin humans1

1 study
  1. Exenatide lowers the risk of mortality in humans (pooled phase 3 RCTs).

    “Semaglutide and exenatide, but not tirzepatide, reduced the risk of all-cause mortality.”

    Human trialpooled phase 3 RCTs

    Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Age-related macular degeneration

upin humans1

1 study
  1. Exenatide is linked with a higher risk of age-related macular degeneration in humans (when taken alone in diabetic patients).

    “The other medication group (exenatide, sitagliptin, and pramlintide) slightly increased the odds of developing AMD when taken alone”

    Humanswhen taken alone in diabetic patients

    INTERACTIONS OF METFORMIN AND OTHER MEDICATIONS IN REDUCING THE ODDS OF AGE-RELATED MACULAR DEGENERATION IN A COHORT OF PATIENTS WITH DIABETES

    Retina (Philadelphia, Pa.)

More on Age-related macular degeneration

Hemoglobin A1c

no changein humans1

1 study
  1. Exenatide is associated with hemoglobin A1c in humans (HbA1c maintained in the 7% range).

    “Exenatide long-acting release (LAR), with an extended administration interval of 1 month, maintained hemoglobin A1c (HbA1c) level in the 7% range.”

    Humansmonthly (1-month interval) administration in elderly patients with poorly controlled type 2 diabeteslong-acting releasen = 2

    Two cases of type 2 diabetes mellitus in elderly patients successfully treated with monthly exenatide long-acting release

    Clinical case reports

More on Hemoglobin A1c

Hypoglycemia

upin humans1

1 study
  1. Exenatide raises the risk of hypoglycemia in humans (type 2 diabetes treated with metformin and a sulfonylurea) (28% (10 microg), 19% (5 microg), 13% (placebo)).

    “The incidence of mild/moderate hypoglycemia was 28% (10 microg), 19% (5 microg), and 13% (placebo)”

    Human trialtype 2 diabetes treated with metformin and a sulfonylurea30 weeks

    Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

    Diabetes care

More on Hypoglycemia

All 13

Has exenatide been tested in people?

46 of 175 about aging

Yes: 14 trials and 47 observational studies in people have been published, and 173 trials are registered.

Approved

Repurposing

40 of 51

Every condition in trials

  • Sexual Infantilism

    Phase 3Completed3 trials

  • Cognition disorder

    Phase 3Status unknown1 trial

  • Alcohol drinking

    Phase 1Terminated1 trial

Stopped

  • NCT00799435TerminatedType 2 diabetes

    Inability to recruit adequate Sample Size who met the entry criteria

  • NCT01381926TerminatedType 2 diabetes

    unavailability of study drug and matching placebo

  • NCT02072096TerminatedType 2 diabetes

    The trial was terminated per protocol because of lack of feasibility.

  • NCT02793154TerminatedType 2 diabetes

    Early termination due to insufficient enrollment.

  • NCT03029351TerminatedType 2 diabetes

    termination by sponsor

  • NCT01791465TerminatedDiabetes mellitus

    This study was terminated after 6 patients due to loss of funding

All 9

Trial sponsors

Funding

7 grants since 2016

National Institute on Drug Abuse$2.7MNational Institute on Alcohol Abuse and Alcoholism$464KNational Institute for Health Research£2M

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 7Jan 2026: 20Feb 2026: 13Mar 2026: 20Apr 2026: 4May 2026: 1Jun 2026: 6Jul 2026: 6Aug 2026: 7Sep 2026: 9Oct 2026: 18Nov 2026: 16127 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Drug use linked to longer survival with high lung blood pressure

Five-year survival was 77.7% among users of drugs including semaglutide, versus 68.5% among nonusers in adults with precapillary pulmonary hypertension.Five-year survival was 77.7% among users of drugs including semaglutide, versus 68.5% among nonusers in adults with precapillary pulmonary hypertension.

Cohort · 11,558 peopleInterventions
AHA Scientific Sessions 2026 Abstract

Death rates differed in statin users with obesity and artery disease

Among statin users with obesity and artery disease, starting one of five added drugs was linked to three-year death rates of 4.0% versus 7.5% with statins alone.Among statin users with obesity and artery disease, starting one of five added drugs was linked to three-year death rates of 4.0% versus 7.5% with statins alone.

Cohort · 239,822 peopleObesity
AHA Scientific Sessions 2026 Abstract

Exenatide lowered protein-based age scores in people

Over 12 months, exenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo in people with type 2 diabetes.Over 12 months, exenatide lowered six organ-related age scores and limited a liver score’s rise compared with placebo in people with type 2 diabetes.

Randomized trial · 3,973 peopleExenatide

See all 246 papers on exenatide